Oscar Health, Inc. (NYSE:OSCR) has reported a significant transaction by its Chief Financial Officer, Richard Scott Blackley, who sold a batch of company shares. The transaction, which took place on September 6, 2024, involved the sale of 29,957 shares at an average price of $17.06 per share, amounting to a total value of over $511,000.
The sale was conducted under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which Blackley had entered into to cover tax obligations related to the vesting of equity awards. According to the filing, the shares were sold at varying prices ranging from $16.68 to $17.48. Following the sale, Blackley's direct holdings in Oscar Health decreased to 853,875 shares of Class A Common Stock.
In addition to the sale, Blackley also acquired 62,500 shares through the exercise of restricted stock units (RSUs) on September 5, 2024. These units were part of an award that began vesting in December 2021 and continue to vest quarterly. It's worth noting that no monetary transaction took place during this acquisition, as RSUs represent a right to receive stock once certain conditions are met, typically linked to the recipient's service to the company.
Investors and market watchers often look to insider transactions as a signal of executives' confidence in their company's prospects. In this case, the sale to cover tax obligations is a routine transaction that executives undertake when their equity awards vest.
Oscar Health, headquartered in New York, operates within the healthcare sector, providing medical service plans. The company, formerly known as Mulberry Health Inc., has been publicly traded and continues to be a subject of interest for investors tracking insider activity and company performance.
In other recent news, Oscar Health's Q2 results have shown strong performance, with total revenue reaching $2.2 billion, marking a 46% increase year-over-year. The company's medical loss ratio improved, and adjusted EBITDA saw significant growth. Oscar Health has revised its full-year 2024 revenue and adjusted EBITDA guidance upwards, with revenue guidance increased by 8.4% at the midpoint and adjusted EBITDA seeing a 23.3% hike.
Piper Sandler has responded to these developments by raising Oscar Health's stock target from $25.00 to $28.00, retaining an Overweight rating on the stock. This decision follows the company's impressive performance in Q2 of 2024, which surpassed both Piper Sandler's and consensus estimates in terms of growth and profitability.
Membership growth is cited as a key driver behind the positive results and raised guidance. Oscar Health's strategic focus on expanding its market presence and diversifying growth through the Individual Coverage Health Reimbursement Arrangement (ICRA) business is central to its long-term financial goals. These recent developments underscore Oscar Health's financial strength and strategic initiatives aimed at long-term growth.
InvestingPro Insights
Amidst the insider transactions at Oscar Health, Inc. (NYSE:OSCR), the company's financial performance and market valuation metrics offer a broader context for investors. According to recent data, Oscar Health's market capitalization stands at approximately $4.22 billion. The company's price-to-earnings (P/E) ratio is notably high at 222.28, suggesting that the stock is trading at a premium relative to its earnings. This is further emphasized by a negative adjusted P/E ratio for the last twelve months as of Q2 2024, which stands at -196.86, indicating expectations of future earnings growth.
InvestingPro Tips highlight that analysts predict Oscar Health will be profitable this year, which aligns with the company's impressive revenue growth of 45.16% over the last twelve months as of Q2 2024. However, analysts have also revised their earnings downwards for the upcoming period, reflecting some caution amidst the optimism. The company's stock price has experienced significant volatility, with a 163.41% return over the last year, yet recent short-term trends show a decline, with a 7.16% decrease in the 1-week price total return as of late 2024.
For investors considering Oscar Health's future prospects, it is important to note that the company does not pay a dividend, which may influence investment strategies focused on income generation. For a deeper analysis and additional insights on Oscar Health, including the full list of 10 InvestingPro Tips, visit the dedicated page at https://www.investing.com/pro/OSCR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.